235 related articles for article (PubMed ID: 30470436)
1. α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease.
Kang JJ; Kaissarian NM; Desch KC; Kelly RJ; Shu L; Bodary PF; Shayman JA
Kidney Int; 2019 Jan; 95(1):149-159. PubMed ID: 30470436
[TBL] [Abstract][Full Text] [Related]
2. Decreased nitric oxide bioavailability in a mouse model of Fabry disease.
Shu L; Park JL; Byun J; Pennathur S; Kollmeyer J; Shayman JA
J Am Soc Nephrol; 2009 Sep; 20(9):1975-85. PubMed ID: 19628671
[TBL] [Abstract][Full Text] [Related]
3. Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in α-galactosidase A.
Kang JJ; Shu L; Park JL; Shayman JA; Bodary PF
Am J Physiol Gastrointest Liver Physiol; 2014 Jan; 306(2):G140-6. PubMed ID: 24232002
[TBL] [Abstract][Full Text] [Related]
4. Dissociation of globotriaosylceramide and impaired endothelial function in α-galactosidase-A deficient EA.hy926 cells.
Kaissarian N; Kang J; Shu L; Ferraz MJ; Aerts JM; Shayman JA
Mol Genet Metab; 2018 Dec; 125(4):338-344. PubMed ID: 30413389
[TBL] [Abstract][Full Text] [Related]
5. Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect.
Park JL; Whitesall SE; D'Alecy LG; Shu L; Shayman JA
Clin Exp Pharmacol Physiol; 2008 Oct; 35(10):1156-63. PubMed ID: 18565198
[TBL] [Abstract][Full Text] [Related]
6. Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease.
Shu L; Vivekanandan-Giri A; Pennathur S; Smid BE; Aerts JM; Hollak CE; Shayman JA
Kidney Int; 2014 Jul; 86(1):58-66. PubMed ID: 24402087
[TBL] [Abstract][Full Text] [Related]
7. Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse.
Park JL; Shu L; Shayman JA
Am J Physiol Heart Circ Physiol; 2009 Apr; 296(4):H1133-40. PubMed ID: 19202000
[TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of Fabry disease endothelial cells with an extended lifespan.
Shen JS; Meng XL; Schiffmann R; Brady RO; Kaneski CR
Mol Genet Metab; 2007; 92(1-2):137-44. PubMed ID: 17644384
[TBL] [Abstract][Full Text] [Related]
9. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
[TBL] [Abstract][Full Text] [Related]
10. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.
Namdar M; Gebhard C; Studiger R; Shi Y; Mocharla P; Schmied C; Brugada P; Lüscher TF; Camici GG
PLoS One; 2012; 7(4):e36373. PubMed ID: 22558451
[TBL] [Abstract][Full Text] [Related]
11. Alpha-galactosidase A in vascular disease.
Bodary PF; Shayman JA; Eitzman DT
Trends Cardiovasc Med; 2007 May; 17(4):129-33. PubMed ID: 17482095
[TBL] [Abstract][Full Text] [Related]
12. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency.
Bodary PF; Shen Y; Vargas FB; Bi X; Ostenso KA; Gu S; Shayman JA; Eitzman DT
Circulation; 2005 Feb; 111(5):629-32. PubMed ID: 15668341
[TBL] [Abstract][Full Text] [Related]
13. An in vitro model of Fabry disease.
Shu L; Murphy HS; Cooling L; Shayman JA
J Am Soc Nephrol; 2005 Sep; 16(9):2636-45. PubMed ID: 16033856
[TBL] [Abstract][Full Text] [Related]
14. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
[TBL] [Abstract][Full Text] [Related]
15. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.
Bangari DS; Ashe KM; Desnick RJ; Maloney C; Lydon J; Piepenhagen P; Budman E; Leonard JP; Cheng SH; Marshall J; Thurberg BL
Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976
[TBL] [Abstract][Full Text] [Related]
16. Priapism in a Fabry disease mouse model is associated with upregulated penile nNOS and eNOS expression.
Meng XL; Arning E; Wight-Carter M; Day TS; Jabbarzadeh-Tabrizi S; Chen S; Ziegler RJ; Bottiglieri T; Schneider JW; Cheng SH; Schiffmann R; Shen JS
J Inherit Metab Dis; 2018 Mar; 41(2):231-238. PubMed ID: 29110178
[TBL] [Abstract][Full Text] [Related]
17. Normal hearing in alpha-galactosidase A-deficient mice, the mouse model for Fabry disease.
Noben-Trauth K; Neely H; Brady RO
Hear Res; 2007 Dec; 234(1-2):10-4. PubMed ID: 17933476
[TBL] [Abstract][Full Text] [Related]
18. Voluntary wheel running activates Akt/AMPK/eNOS signaling cascades without improving profound endothelial dysfunction in mice deficient in α-galactosidase A.
Kang JJ; Treadwell TA; Bodary PF; Shayman JA
PLoS One; 2019; 14(5):e0217214. PubMed ID: 31120949
[TBL] [Abstract][Full Text] [Related]
19. Intracellular receptor EPAC regulates von Willebrand factor secretion from endothelial cells in a PI3K-/eNOS-dependent manner during inflammation.
Xiao J; Zhang B; Su Z; Liu Y; Shelite TR; Chang Q; Qiu Y; Bei J; Wang P; Bukreyev A; Soong L; Jin Y; Ksiazek T; Gaitas A; Rossi SL; Zhou J; Laposata M; Saito TB; Gong B
J Biol Chem; 2021 Nov; 297(5):101315. PubMed ID: 34678311
[TBL] [Abstract][Full Text] [Related]
20. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease.
Choi S; Kim JA; Na HY; Cho SE; Park S; Jung SC; Suh SH
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):81-9. PubMed ID: 24158513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
